Therapeutic potential of bone marrow-derived mesenchymal stem cells producing pigment epithelium-derived factor in lung carcinoma

Chen,Qiaoling; Cheng,Ping; Yin,Tao; He,Hong; Yang,Li; Wei,Yuquan; Chen,Xiancheng

doi:10.3892/ijmm.2012.1015

Therapeutic potential of bone marrow-derived mesenchymal stem cells producing pigment epithelium-derived factor in lung carcinoma

Authors:
- Qiaoling Chen
- Ping Cheng
- Tao Yin
- Hong He
- Li Yang
- Yuquan Wei
- Xiancheng Chen
View Affiliations

Affiliations: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, P.R. China
Published online on: June 6, 2012 https://doi.org/10.3892/ijmm.2012.1015
Pages: 527-534

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Specific and efficient gene delivery to target cells and the subsequent expression of the RNA and protein is crucial to the success of gene-based therapy for cancer. Mesenchymal stem cells (MSCs) represent novel and efficient tools for delivery of therapeutic agents to tumor cells. In this study, we evaluated the potential of bone marrow-derived mesenchymal stem cells, genetically modified to express pigment epithelium-derived factor (PEDF) for the treatment of Lewis lung carcinoma (LLC). MSCs derived from murine bone marrow were efﬁciently engineered to express human PEDF by adenoviral transduction, and the expression and bioactivity of the transgenic protein from engineered MSCs were confirmed in vitro. Animal experiments showed that the systemic administration of MSCs treated with PEDF dramatically reduced the growth of LLC tumors and significantly prolonged survival. Immunohistochemistry analysis of the tumors from MSC-PEDF-treated animals indicated an increase in apoptosis and a decrease in microvessel density. ELISA showed that the group of MSCs treated with PEDF had relatively higher expression levels of PEDF in tumor tissue and lower levels in serum compared with the free Ad-PEDF group. These results suggest that MSCs have potential use as effective delivery of vehicles for therapeutic genes in the treatment of LLC.

View Figures

View References

1.	J FerlayP AutierM BoniolM HeanueM ColombetP BoyleEstimates of the cancer incidence and mortality in Europe in 2006Ann Oncol18581592200710.1093/annonc/mdl49817287242
2.	DM ParkinF BrayJ FerlayP PisaniGlobal cancer statistics, 2002CA Cancer J Clin5574108200510.3322/canjclin.55.2.74
3.	DS EttingerW AkerleyG BeplerNon-small cell lung cancerJ Natl Compr Cancer Netw8740801201020679538
4.	A JemalR SiegelE WardY HaoJ XuMJ ThunCancer statistics, 2009CA Cancer J Clin59225249200910.3322/caac.20006
5.	J FolkmanY ShingAngiogenesisJ Biol Chem26710931109341992
6.	VW van HinsberghA CollenP KoolwijkAngiogenesis and anti-angiogenesis: perspectives for the treatment of solid tumorsAnn Oncol10Suppl 4S60S63199910436787
7.	CR DassTM TranPF ChoongAngiogenesis inhibitors and the need for anti-angiogenic therapeuticsJ Dent Res86927936200710.1177/15440591070860100517890668
8.	ET EkCR DassPF ChoongPigment epithelium-derived factor: a multimodal tumor inhibitorMol Cancer Ther516411646200610.1158/1535-7163.MCT-06-010716891449
9.	FR SteeleGJ ChaderLV JohnsonJ Tombran-TinkPigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene familyProc Natl Acad Sci USA9015261530199310.1073/pnas.90.4.15268434014
10.	DW DawsonOV VolpertP GillisPigment epithelium-derived factor: a potent inhibitor of angiogenesisScience285245248199910.1126/science.285.5425.24510398599
11.	JA DollVM StellmachNP BouckPigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreasNat Med9774780200310.1038/nm87012740569
12.	R HaseM MiyamotoH UeharaPigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in miceClin Cancer Res1187378744200510.1158/1078-0432.CCR-05-132316361561
13.	M GuanHF YamB SuLoss of pigment epithelium derived factor expression in glioma progressionJ Clin Pathol56277282200310.1136/jcp.56.4.27712663639
14.	J YangS ChenX HuangGrowth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesisCancer Biol Ther9967974201010.4161/cbt.9.12.1163520364117
15.	L WangV SchmitzA Perez-MediavillaI IzalJ PrietoC QianSuppression of angiogenesis and tumor growth by adenoviral-mediated gene transfer of pigment epithelium-derived factorMol Ther87279200310.1016/S1525-0016(03)00128-X12842430
16.	BD RoordaA ter ElstWA KampsES de BontBone marrow-derived cells and tumor growth: contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cellsCrit Rev Oncol Hematol69187198200910.1016/j.critrevonc.2008.06.00418675551
17.	MF PittengerAM MackaySC BeckMultilineage potential of adult human mesenchymal stem cellsScience284143147199910.1126/science.284.5411.14310102814
18.	N EliopoulosA Al-KhaldiM CrosatoK LachapelleJ GalipeauA neovascularized organoid derived from retrovirally engineered bone marrow stroma leads to prolonged in vivo systemic delivery of erythropoietin in nonmyeloablated, immunocompetent miceGene Ther10478489200310.1038/sj.gt.3301919
19.	SH SeoKS KimSH ParkThe effects of mesenchymal stem cells injected via different routes on modified IL-12-mediated antitumor activityGene Ther18488495201110.1038/gt.2010.17021228885
20.	U GalderisiA GiordanoMG PaggiThe bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agentsWorld J Stem Cells2512201010.4252/wjsc.v2.i1.521607110
21.	M StudenyFC MariniRE ChamplinC ZompettaIJ FidlerM AndreeffBone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumorsCancer Res6236033608200212097260
22.	EA JaffeRL NachmanCG BeckerCR MinickCulture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteriaJ Clin Invest5227452756197310.1172/JCI1074704355998
23.	N EliopoulosM FrancoisMN BoivinD MartineauJ GalipeauNeo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapyCancer Res6848104818200810.1158/0008-5472.CAN-08-016018559528
24.	S BobisD JarochaM MajkaMesenchymal stem cells: characteristics and clinical applicationsFolia Histochem Cytobiol44215230200617219716
25.	LP YangP ChengXC PengAntitumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16–F10 melanomaJ Exp Clin Cancer Res2875200919500366
26.	JY LiuYQ WeiL YangImmunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2Blood10218151823200310.1182/blood-2002-12-377212750177
27.	X PangZ YiX ZhangAcetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesisCancer Res6958935900200910.1158/0008-5472.CAN-09-075519567671
28.	S ZhangZ CaoH TianSKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivoClin Cancer Res1744394450201110.1158/1078-0432.CCR-10-310921622720
29.	KA MohamedaliD KedarP SweeneyThe vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumorsNeoplasia7912920200510.1593/neo.0529216242074
30.	G TarabolettiR GiavazziModelling approaches for angiogenesisEur J Cancer40881889200410.1016/j.ejca.2004.01.00215120043
31.	V FritzC JorgensenMesenchymal stem cells: an emerging tool for cancer targeting and therapyCurr Stem Cell Res Ther33242200810.2174/15748880878348946218220921
32.	X ChenX LinJ ZhaoA tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCsMol Ther16749756200810.1038/mt.2008.318362930
33.	Y GaoA YaoW ZhangHuman mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude miceOncogene2927842794201010.1038/onc.2010.38